Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor

Head and Neck Cancer Clinical Trial

Official title:

A Phase II Clinical Study to Evaluate the Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01684098
• Other study ID #: EC20.8
• Status: Completed
• Phase: Phase 2
• Start date: August 2003
• Est. completion date: August 2005

Study information

• Verified date: September 2012
• Source: Endocyte
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The folate receptor is over-expressed on many types of cancer cells and new folate receptor targeted therapies are being developed to target cancer cells that over-express the folate receptor. As with other targeted therapies, it is important to develop diagnostic tests that will provide accurate information on folate receptor status and aid in selecting patients that may benefit from folate-targeted therapy.

Description:

This Phase II, limited institution, open-label, single-arm, baseline-controlled study is designed to obtain data on the percentage of patients with recurrent or metastatic cancer from a solid tumor (including, but not limited to, breast, lung, mesothelioma, liver, colorectal, prostate, head and neck, pancreas, bladder and testicular cancer) with increased uptake of FalateScan in tumors, correlate the immunohistochemical staining findings with the FolateScan images, and verify product safety in patients with suspected recurrent or metastatic disease from any solid tumor.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: August 2005
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must meet the following eligibility requirements to be enrolled in the study:

1. Patient must be 18 years of age or older.

2. Patient must have known or strongly suspected recurrent or metastatic cancer from a solid tumor with at least one identifiable lesion > 1.5 cm as diagnosed by conventional imaging.

3. Patient must have adequate kidney function defined as serum creatinine of < 1.5 X ULN.

4. Patient must have adequate liver function defined as transaminases (SGOT and/or SGPT) may be up to 2.5 X ULN if alkaline phosphatase is <ULN or alkaline phosphatase may be up to 2.5 X ULN if Transaminases are < ULN. If alkaline phosphatase is outside of these parameters and is due to bone metastases verified by assessment of isoenzymes, then the subject is eligible.

5. Patient must provide written informed consent prior to enrollment.

Exclusion Criteria:

• Patients must be excluded in any of the following conditions are present:

1. Patient is pregnant or breastfeeding.

2. Patient is simultaneously participating in another investigational drug study, excluding the follow-up phase.

3. Patient has received an investigational agent within 7 days prior to enrollment.

4. Patient is unable to tolerate conditions for radionuclide imaging.

5. Patient has been administered another radiopharmaceutical that would interfere with the assessment of Technetium Tc 99m EC20.

Related Conditions & MeSH terms

• Bladder Cancer
• Head and Neck Cancer
• Head and Neck Neoplasms
• Neoplasm Metastasis
• Neoplasms
• Neoplasms, Second Primary
• Pancreas Cancer
• Pancreatic Neoplasms
• Recurrence
• Recurrent or Metastatic Cancer
• Testicular Cancer
• Testicular Neoplasms
• Urinary Bladder Neoplasms

Intervention

Drug:
• Tc 99m EC20

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Endocyte